Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva/Gazyvaro, an anti-CD20 monoclonal antibody designed for enhanced B cell depletionGazyva/Gazyvaro has the potential to b ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today statistically significant and clinically meaningful results from the Phase III ALLEGORY study of Gazyva® ...

Data will be presented at an upcoming medical meeting and shared with health authorities as soon as possible, including the US Food and Drug Administration and the European Medicines Agency. If ...

Chronic inflammation may be subtle but can indicate serious health issues. Discover common and surprising symptoms, and learn ...

We were joined by various experts who shared their expert insights, practical tips and candid experiences to help others navigate sex, intimacy and self-confidence while living with lupus.

Falls are common among adults with SLE and are linked to several factors, including higher disease activity, organ damage, and polypharmacy.

A popular online athleisure wear company supporting lupus research is opening their first brick-and-mortar location in Springfield.

Background Anti-C1q autoantibodies can disrupt normal complement function, contributing to the formation of pathogenic immune ...

CHICAGO -- People who died with systemic lupus erythematosus (SLE) were far more likely than car crash victims to have severe ...

Fibromyalgia was considered a comorbidity rather than a rheumatic disease, but was present in about 10% of patients. Other ...

Obexelimab met primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo, p=0.0009 ...

Integrated analyses of the Phase 2 PAISLEY-SLE and PAISLEY LTE studies showed that Sotyktu maintained a consistent safety profile and durable efficacy in patients with moderate-to-severe SLE with up ...